相关实验视频

Updated: Jun 1, 2025

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

分析血小板形态参数作为急性冠状动脉综合征的临床风险分层

Xuguang Zhang¹, Zhiwei Huang², Xin Wang¹

¹Department of Cardiology, The Second Hospital of Shandong University, Jinan, Shandong, People's Republic of China.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

|January 20, 2025

概括

血小板形态参数如MPV,PDW和P-LCR在急性冠状动脉综合征 (ACS) 患者中升高. 这些标志物预测冠状动脉严重程度和不良结果,综合评估改善了风险分层.

科学领域:

心脏病学心脏病学
血液学血液学血液学
生物标志物发现发现

背景情况:

血小板激活是急性冠状动脉综合征 (ACS) 发病的关键.
血小板形态参数,包括平均血小板体积 (MPV),血小板分布宽度 (PDW) 和血小板大细胞比率 (P-LCR),正在成为重要的生物标志物.
这些参数显示出预测ACS严重程度和患者预后的潜力.

研究的目的:

研究MPV,PDW和P-LCR之间的关系以及ACS患者冠状动脉病变的严重程度.
评估这些血小板参数对不良临床结果的预测值.
在ACS中评估这些参数的诊断性能.

主要方法:

一项前性观察性研究,涉及134名ACS患者和50名健康对照.
在入院时测量MPV,PDW和P-LCR.
冠状动脉损伤严重程度通过冠状动脉血管学评估,使用根西尼得分进行评估.
多变量逻辑回归和ROC曲线分析以确定预测和诊断值.

主要成果:

与对照组相比,ACS患者的MPV,PDW和P-LCR显著增加 (p < 0.001).
这些血小板参数与根西尼评分 (r = 0.7780.800; p < 0.001) 之间观察到强烈的正相关性.
MPV,PDW和P-LCR被确定为不良预后的独立预测因素 (p < 0.001).
对MPV,PDW和P-LCR的综合评估显示出更高的预测准确性 (AUC = 0.927).

结论:

血小板形态参数升高与ACS中的冠状动脉病变严重程度密切相关.
这些参数是ACS患者不良结果的独立预测指标.
对MPV,PDW和P-LCR的综合评估提供了增强的风险分层,有助于治疗指导和预后改善.

关键词:

急性冠状动脉综合征急性冠状动脉综合征平均血小板体积 (MPV)血小板的分布宽度 (PDW)血小板大细胞比率 (P-LCR)风险分层的分层化

更多相关视频

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...